<i>Phaeodactylum tricornutum</i> as Fucoxanthin Biofactory Model and Hepatoprotective Effect of Encapsulated Spirulina and Fucoxanthin

Abstract

In recent decades, the worldwide production of microalgae has been carried out on an industrial scale. In recent years, the market for natural products has grown because of changes in consumer preferences for more natural products. The objective of this study was to demonstrate the hepatoprotective capacity of fucoxanthin extract obtained from an industrial culture of the microalgae Phaeodactylum tricornutum (Culture Collection of Alga and Protists in Scotland). The microalga was grown in an artificial and natural seawater mixture (1:9), using Walne’s culture medium in columns and raceway photobioreactors (RWP) inside a greenhouse. The carotenoid content in the tested systems continued to increase from day 5 of the culture, when the stationary phase was reached. The final biomass powder contained 4.9 mg (2.59%) of pure fucoxanthin. The possible hepatoprotective activity of fucoxanthin was then studied in the HepG2 cell line for 24 h in culture, and compared with the cytotoxicity of methotrexate (MTX). In conclusion, the active ingredient showed hepatoprotective activity against MTX in the human hepatocyte cell line HEPG-2 at a concentration of 0.25 mg/mL. The current results also suggest that it has beneficial properties for liver health and is a suitable ingredient for all types of nutraceutical products.

Keywords

• microalgae
• fucoxanthin
• hepatoprotective
• <i>Phaeodactylum</i>
• biofactory